CST9L

Across TCGA pan-cancer cohorts, CST9L mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CST9L data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CST9L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CST9L expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where CST9L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.453	0.934	.005	64	view →
PDAC	OS	Median	All	0.267	0.612	.010	19	view →
LUAD	DFS	Quartile	III,IV	0.353	1.000	.024	3	view →
HNSC	OS	Median	III,IV	0.641	0.809	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CST9L–CCRCC (DFS)

Open the CCRCC breakdown →